- First
medical cannabis producer in North America to meet rigorous standards of
GMP certification, supplying cannabis flower and extracts
- Canadian
federally-licensed cannabis cultivator, processor and distributor
- Q2
2018 revenue increased to $9.7 million, up 95.2 percent over second
quarter of 2017
- Multinational
distribution network makes Tilray medical cannabis available to patients
in 11 countries on five continents
- Raised
$163.6 million in a successful IPO in July 2018 and $55 million from
leading institutional investors prior to IPO
- Agreements
signed to supply medical cannabis via Canadian pharmacies and recreational
cannabis to adult-use consumers in seven Canadian provinces and
territories
- Received
U.S. government approval to import cannabinoid study drug to UC San Diego
for clinical trial for treatment of essential tremor, a neurological disorder
Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis
research, cultivation, production and distribution, continues to build an
international footprint in the cannabis space with a long list of “firsts” in
the cannabis industry. As one of only a few cannabis companies with a U.S.
stock listing, Tilray’s stock has been a favorite of investors, soaring more
than 10-fold since its initial public offering in July. Tilray’s diverse
management team of industry leading experts includes PhD research scientists,
master horticulturalists, engineers and patient advocates, in addition to
backing by billionaire investor Peter Thiel.
Tilray’s aggressive pursuit of agreements to supply premium
cannabis products to not only the Canadian market, which is poised to become
the first G7 country to legalize recreational cannabis nationwide in October,
but to any country that has legalized cannabis. Among its most recent
announcements, the company has:
- Executed
a non-binding letter of intent with IntelGenx Corp. to co-develop and
commercialize oral film products infused with recreational and medical
cannabis (http://ibn.fm/OAFLK)
- Received
approval from the U.S. Drug Enforcement Administration (DEA) to import a
medical cannabis supply drug for a clinical trial on essential tremor at
the University of California San Diego Center for Medicinal Cannabis
Research (http://ibn.fm/dXv4s)
- Regulatory
permits approved for export to Germany of medical cannabis flower and
full-spectrum medical cannabis oil for patient use (http://ibn.fm/BAgNU)
- Currently
supplying products for several different clinical trials in partnership
with universities, hospitals and governments in Australia and
Canada (http://ibn.fm/gIv0T)
- Established
wholly owned subsidiary High Park Company to produce and distribute a
broad-based portfolio of cannabis brands and products in Canada; an
investment totaling $100 million that’s expected to grow the company’s
Canadian workforce to more than 500 in the next several years
In Deloitte’s 2018 cannabis report (http://ibn.fm/4vTb5), the
research firm frames the total cannabis market in Canada as “significant” and
one that has “spurred innovation, entrepreneurship and jobs.” Canada’s medical
and recreational cannabis market is expected to generate $7.17 billion in total
sales in 2019.
Brendan Kennedy, president and chief executive officer of
Tilray, notes the company’s strong start to 2018 and offers insight to its
future plans in a second quarter earnings report to stakeholders (http://ibn.fm/WNKql).
“Tilray is well-positioned to continue to pioneer the
development of the global medical cannabis market and to become a leader in the
adult-use cannabis market in Canada,” Kennedy states in the report. “In the
second quarter, we generated significant revenue growth as a result of our
global strategy, our multinational distribution network and our commitment to
research, innovation, quality and operational excellence.”
Financial highlights in the report include an increase in
revenue to $9.7 million, up 95.2 percent compared to the second quarter of
2017; a 97 percent increase in total kilogram equivalents sold compared to the
prior year; and an average net selling price per gram increase from $6.20 to
$6.38.
Business highlights in 2018 to date show Tilray’s successful
IPO and funding received from institutional investors that brought $218.6
million to the company; signed agreements to supply cannabis to adult-use
consumers in seven Canadian provinces and territories and signed strategic
agreements with Sandoz Canada, a division of Novartis, to collaborate on the
creation and sale of co-branded and co-developed non-combustible medical
cannabis products. Agreements or LOIs were also signed with Shoppers Drug Mart
Inc., Canada’s largest pharmacy chain, and Pharmasave, one of Canada’s leading
independent pharmacy chains, to provide Tilray products once certain legal
steps have been met.
Exports to Argentina, South Africa and the United Kingdom
now make Tilray products available in 11 countries on five continents. The
company also launched High Park Holdings Ltd., a wholly owned subsidiary formed
to serve the pending adult-use market in Canada, in addition to the launch of
the CANACA brand, which celebrates the historic moment in Canada as it becomes
the first G7 nation to federally legalize cannabis for adult-use.
Tilray’s company culture promotes experience, precision,
research and care for its customers and clients. Its precisely formulated
products are cultivated to meet exacting patient needs and come in two primary
forms – extracts and dried flower. Tilray’s product line centers on active
ingredients and standardized, well-defined preparations with a focus on patient
safety and efficacy. The company’s clinical research program is designed to
evolve current scientific understanding of the therapeutic value and risks of
cannabinoid-based medicines. Tilray’s flagship production facility is located
in Nanaimo, Vancouver Island, British Columbia.
For more information, visit the company’s website at www.Tilray.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
